1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine has been researched along with Action Tremor in 30 studies
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine: A dopaminergic neurotoxic compound which produces irreversible clinical, chemical, and pathological alterations that mimic those found in Parkinson disease.
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine : A tetrahydropyridine that is 1,2,3,6-tetrahydropyridine substituted by a methyl group at position 1 and a phenyl group at position 4.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The antitremor effect of the D2 agonist LY 171555 and of the D1 agonist CY 208-243 alone and in combination was tested in a monkey previously rendered parkinsonian by MPTP and displaying exceptionally a rest tremor in the limbs." | 7.68 | Effect of LY 171555 and CY 208-243 on tremor suppression in the MPTP monkey model of parkinsonism. ( Bédard, PJ; Boucher, R; Gomez-Mancilla, B, 1992) |
| "Based on the hypothesis that low-threshold calcium conductance in the thalamus might be involved in the pathophysiology of parkinsonian tremor, ethosuximide was given chronically to a monkey previously treated with MPTP and displaying exceptionally a typical rest tremor." | 7.68 | Effect of ethosuximide on rest tremor in the MPTP monkey model. ( Bédard, PJ; Boucher, R; Gomez-Mancilla, B; Latulippe, JF, 1992) |
| "The effect of arotinolol, a peripherally acting beta-adrenergic-blocking agent, on postural or kinetic tremor was studied in monkeys with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced parkinsonism." | 7.68 | Therapeutic effects of arotinolol, a beta-adrenergic blocker, on tremor in MPTP-induced parkinsonian monkeys. ( Kuno, S; Mizuta, E; Nishida, J; Takechi, M, 1992) |
| "The purported alpha 2-adrenergic agonist clonidine was found to inhibit rest tremor at doses of 0." | 7.68 | Effect of clonidine and atropine on rest tremor in the MPTP monkey model of parkinsonism. ( Bédard, PJ; Boucher, R; Gomez-Mancilla, B, 1991) |
| "Morphine has been found to elevate dopamine levels, which indicates a potential therapeutic effect in PD treatment that has not been investigated previously." | 5.40 | Acute morphine treatments alleviate tremor in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkeys. ( Hu, X; Huang, B; Li, H; Ma, Y; Rizak, JD; Yan, T; Yang, S, 2014) |
| " The extract at both the doses displayed a significant reduction in postural flexion, moderate decrease in tremor, muscular rigidity and postural immobility scores but do not exhibit significant lowering of hypokinesia score in reserpine induced Parkinsonian model." | 4.12 | Antiparkinsonian activity of Tabebuia impetiginosa bark and biochemical analysis of dopamine in rat brain homogenates. ( Kadiri, SK; Karkar, VV; Pal Roy, S; Rao Konijeti, S, 2022) |
| "To investigate the role of the basal ganglia in parkinsonian tremor, we recorded hand tremor and simultaneous activity of several neurons in the external and internal segments of the globus pallidus (GPe and GPi) in two vervet monkeys, before and after systemic treatment with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and development of parkinsonism with tremor of 5 and 11 Hz." | 3.70 | Firing patterns and correlations of spontaneous discharge of pallidal neurons in the normal and the tremulous 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine vervet model of parkinsonism. ( Bergman, H; Raz, A; Vaadia, E, 2000) |
| " Three African green monkeys were systemically treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) until parkinsonian signs, including akinesia, rigidity, and a prominent 4- to 8-Hz tremor, appeared." | 3.69 | The primate subthalamic nucleus. II. Neuronal activity in the MPTP model of parkinsonism. ( Bergman, H; DeLong, MR; Karmon, B; Wichmann, T, 1994) |
| "The antitremor effect of the D2 agonist LY 171555 and of the D1 agonist CY 208-243 alone and in combination was tested in a monkey previously rendered parkinsonian by MPTP and displaying exceptionally a rest tremor in the limbs." | 3.68 | Effect of LY 171555 and CY 208-243 on tremor suppression in the MPTP monkey model of parkinsonism. ( Bédard, PJ; Boucher, R; Gomez-Mancilla, B, 1992) |
| "Based on the hypothesis that low-threshold calcium conductance in the thalamus might be involved in the pathophysiology of parkinsonian tremor, ethosuximide was given chronically to a monkey previously treated with MPTP and displaying exceptionally a typical rest tremor." | 3.68 | Effect of ethosuximide on rest tremor in the MPTP monkey model. ( Bédard, PJ; Boucher, R; Gomez-Mancilla, B; Latulippe, JF, 1992) |
| "The effect of arotinolol, a peripherally acting beta-adrenergic-blocking agent, on postural or kinetic tremor was studied in monkeys with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced parkinsonism." | 3.68 | Therapeutic effects of arotinolol, a beta-adrenergic blocker, on tremor in MPTP-induced parkinsonian monkeys. ( Kuno, S; Mizuta, E; Nishida, J; Takechi, M, 1992) |
| "We assessed clinical and electrophysiologic characteristics of tremor in patients with parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)." | 3.68 | Tremor in MPTP-induced parkinsonism. ( Langston, JW; Tetrud, JW, 1992) |
| "The purported alpha 2-adrenergic agonist clonidine was found to inhibit rest tremor at doses of 0." | 3.68 | Effect of clonidine and atropine on rest tremor in the MPTP monkey model of parkinsonism. ( Bédard, PJ; Boucher, R; Gomez-Mancilla, B, 1991) |
| "Chronic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) induced parkinsonian symptoms, predominantly bradykinesia and tremor, in marmosets." | 3.67 | Failure of SKF 38393-A to relieve parkinsonian symptoms induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the marmoset. ( Close, SP; Marriott, AS; Pay, S, 1985) |
| "Rest tremor is one of the most prominent clinical features of Parkinson's disease (PD)." | 1.91 | Tuned to Tremor: Increased Sensitivity of Cortico-Basal Ganglia Neurons to Tremor Frequency in the MPTP Nonhuman Primate Model of Parkinson's Disease. ( Bergman, H; Eitan, R; Linkovski, O; Mevorach, T; Rahamim, N; Rosin, B; Slovik, M, 2023) |
| "A moving tremor was also observed by visual inspection during this period." | 1.56 | Measurement of baseline locomotion and other behavioral traits in a common marmoset model of Parkinson's disease established by a single administration regimen of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: providing reference data for efficacious precl ( Ando, K; Hikishima, K; Inoue, R; Inoue, T; Kawai, K; Komaki, Y; Nishime, C; Nishinaka, E; Okano, H; Urano, K, 2020) |
| "The nonhuman primate model of Parkinson's disease emulates the cardinal symptoms of the disease, including tremor, rigidity, bradykinesia, postural instability, freezing and cognitive impairment." | 1.48 | Charting the onset of Parkinson-like motor and non-motor symptoms in nonhuman primate model of Parkinson's disease. ( Choudhury, GR; Daadi, MM, 2018) |
| "Morphine has been found to elevate dopamine levels, which indicates a potential therapeutic effect in PD treatment that has not been investigated previously." | 1.40 | Acute morphine treatments alleviate tremor in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkeys. ( Hu, X; Huang, B; Li, H; Ma, Y; Rizak, JD; Yan, T; Yang, S, 2014) |
| "The tremor is intermittent and does not appear in all human patients." | 1.36 | Computational physiology of the basal ganglia in Parkinson's disease. ( Bergman, H; Elias, S; Heimer, G; Rivlin-Etzion, M, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (6.67) | 18.7374 |
| 1990's | 13 (43.33) | 18.2507 |
| 2000's | 7 (23.33) | 29.6817 |
| 2010's | 5 (16.67) | 24.3611 |
| 2020's | 3 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Pal Roy, S | 1 |
| Kadiri, SK | 1 |
| Karkar, VV | 1 |
| Rao Konijeti, S | 1 |
| Rahamim, N | 1 |
| Slovik, M | 1 |
| Mevorach, T | 1 |
| Linkovski, O | 1 |
| Bergman, H | 5 |
| Rosin, B | 1 |
| Eitan, R | 1 |
| Ando, K | 1 |
| Inoue, T | 1 |
| Hikishima, K | 1 |
| Komaki, Y | 1 |
| Kawai, K | 1 |
| Inoue, R | 1 |
| Nishime, C | 1 |
| Nishinaka, E | 1 |
| Urano, K | 1 |
| Okano, H | 1 |
| Pérez-Rodríguez, M | 1 |
| García-Mendoza, E | 1 |
| Farfán-García, ED | 1 |
| Das, BC | 1 |
| Ciprés-Flores, FJ | 1 |
| Trujillo-Ferrara, JG | 1 |
| Tamay-Cach, F | 1 |
| Soriano-Ursúa, MA | 1 |
| Rosa, AI | 1 |
| Duarte-Silva, S | 1 |
| Silva-Fernandes, A | 1 |
| Nunes, MJ | 1 |
| Carvalho, AN | 1 |
| Rodrigues, E | 1 |
| Gama, MJ | 1 |
| Rodrigues, CMP | 1 |
| Maciel, P | 1 |
| Castro-Caldas, M | 1 |
| Choudhury, GR | 1 |
| Daadi, MM | 1 |
| Yan, T | 1 |
| Rizak, JD | 1 |
| Yang, S | 1 |
| Li, H | 1 |
| Huang, B | 1 |
| Ma, Y | 1 |
| Hu, X | 1 |
| Minematsu, M | 1 |
| Nakajima, K | 1 |
| Rivlin-Etzion, M | 1 |
| Elias, S | 1 |
| Heimer, G | 1 |
| Schneider, JS | 1 |
| Gonczi, H | 1 |
| Decamp, E | 1 |
| Haobam, R | 1 |
| Sindhu, KM | 1 |
| Chandra, G | 1 |
| Mohanakumar, KP | 1 |
| Dhanasekaran, M | 1 |
| Uthayathas, S | 1 |
| Karuppagounder, SS | 1 |
| Parameshwaran, K | 1 |
| Suppiramaniam, V | 1 |
| Ebadi, M | 1 |
| Brown-Borg, HM | 1 |
| Wichmann, T | 2 |
| Karmon, B | 1 |
| DeLong, MR | 2 |
| Curti, D | 1 |
| Izzo, E | 1 |
| Benzi, G | 1 |
| Braham, J | 1 |
| Raz, A | 2 |
| Feingold, A | 1 |
| Nini, A | 1 |
| Nelken, I | 1 |
| Hansel, D | 1 |
| Ben-Pazi, H | 1 |
| Reches, A | 1 |
| Eberling, JL | 1 |
| Pivirotto, P | 1 |
| Bringas, J | 1 |
| Bankiewicz, KS | 1 |
| Vaadia, E | 1 |
| Emborg, ME | 1 |
| Shin, P | 1 |
| Roitberg, B | 1 |
| Sramek, JG | 1 |
| Chu, Y | 1 |
| Stebbins, GT | 1 |
| Hamilton, JS | 1 |
| Suzdak, PD | 1 |
| Steiner, JP | 1 |
| Kordower, JH | 1 |
| Gomez-Mancilla, B | 3 |
| Boucher, R | 3 |
| Bédard, PJ | 3 |
| Latulippe, JF | 1 |
| Kuno, S | 1 |
| Mizuta, E | 1 |
| Nishida, J | 1 |
| Takechi, M | 1 |
| Colpaert, FC | 3 |
| Degryse, AD | 3 |
| Van Craenendonck, HV | 1 |
| Tetrud, JW | 1 |
| Langston, JW | 1 |
| Mavridis, M | 1 |
| Lategan, AJ | 1 |
| Marien, MR | 1 |
| Tal, E | 1 |
| Nir, I | 1 |
| Kalman, R | 1 |
| Yanai, J | 1 |
| Close, SP | 1 |
| Marriott, AS | 1 |
| Pay, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Convection Enhanced Delivery of Muscimol to Study the Pathophysiology Underlying the Clinical Features of Parkinson's Disease[NCT00921128] | Phase 1 | 0 participants (Actual) | Interventional | 2009-06-02 | Withdrawn | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and Action Tremor
| Article | Year |
|---|---|
Pathophysiology of parkinsonian motor abnormalities.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Basal Ganglia; Brain Mapping; Cerebral Cortex | 1993 |
29 other studies available for 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and Action Tremor
| Article | Year |
|---|---|
Antiparkinsonian activity of Tabebuia impetiginosa bark and biochemical analysis of dopamine in rat brain homogenates.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adjuvants, Immunologic; Animals; Antioxidants; Antipar | 2022 |
Tuned to Tremor: Increased Sensitivity of Cortico-Basal Ganglia Neurons to Tremor Frequency in the MPTP Nonhuman Primate Model of Parkinson's Disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Basal Ganglia; Female; Globus Pallidus; Neuro | 2023 |
Measurement of baseline locomotion and other behavioral traits in a common marmoset model of Parkinson's disease established by a single administration regimen of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: providing reference data for efficacious precl
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Brain; Callithrix; Corpus S | 2020 |
Not all boronic acids with a five-membered cycle induce tremor, neuronal damage and decreased dopamine.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Boronic Acids; Brain; Chromatography, High Pr | 2017 |
Tauroursodeoxycholic Acid Improves Motor Symptoms in a Mouse Model of Parkinson's Disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Gait; Hindlimb; Homeo | 2018 |
Charting the onset of Parkinson-like motor and non-motor symptoms in nonhuman primate model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Age of Onset; Animals; Callithrix; Circadian Rhythm; D | 2018 |
Acute morphine treatments alleviate tremor in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Hypokinesia; Levodopa; Maca | 2014 |
Significant effect of dimethylsulfoniopropionate on Parkinson's disease of senescence-accelerated mice induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Aging; Alzheimer Disea | 2008 |
Computational physiology of the basal ganglia in Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Action Potentials; Animals; Basal Ganglia; Chlorocebus | 2010 |
Development of levodopa-induced dyskinesias in parkinsonian monkeys may depend upon rate of symptom onset and/or duration of symptoms.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Appetite; Behavior, Animal; Blinking; Dopamin | 2003 |
Swim-test as a function of motor impairment in MPTP model of Parkinson's disease: a comparative study in two mouse strains.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Corpus Striatum; Disease Mo | 2005 |
Ebselen effects on MPTP-induced neurotoxicity.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antioxidants; Azoles; Brain; Cell Line, Tumor | 2006 |
The primate subthalamic nucleus. II. Neuronal activity in the MPTP model of parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Afferent Pathways; Animals; Basal Ganglia; Brain Mappi | 1994 |
Alteration of pallidal cholinergic activity in MPTP-treated monkeys: effect of dihydro-alpha-ergocryptine (DEK).
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Acetylcholinesterase; Animals; Brain; Choline O-Acetyl | 1994 |
Parkinsonian tremor.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Humans; Parkinson Disease, Secondary; Tremor | 1993 |
Physiology of MPTP tremor.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Chlorocebus aethiops; Dopamine Agents; Macaca | 1998 |
Tremor is associated with PET measures of nigrostriatal dopamine function in MPTP-lesioned monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Caudate Nucleus; Dopamine; Dopamine Agents; F | 2000 |
Firing patterns and correlations of spontaneous discharge of pallidal neurons in the normal and the tremulous 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine vervet model of parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Action Potentials; Animals; Biological Clocks; Chloroc | 2000 |
Systemic administration of the immunophilin ligand GPI 1046 in MPTP-treated monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Administration, Oral; Animals; Brain; Carotid Arteries | 2001 |
Effect of LY 171555 and CY 208-243 on tremor suppression in the MPTP monkey model of parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Dopamine Agents; Dose-R | 1992 |
Effect of ethosuximide on rest tremor in the MPTP monkey model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Diltiazem; Dopamine Agents; Dose-Response Rel | 1992 |
Therapeutic effects of arotinolol, a beta-adrenergic blocker, on tremor in MPTP-induced parkinsonian monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adrenergic beta-Antagonists; Animals; Macaca fascicula | 1992 |
Effects of an alpha 2 antagonist in a 20-year-old Java monkey with MPTP-induced parkinsonian signs.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adrenergic alpha-Antagonists; Animals; Blinking; Locus | 1991 |
Tremor in MPTP-induced parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adult; Electromyography; Female; Humans; Male; Parkins | 1992 |
Effects of locus coeruleus lesions on parkinsonian signs, striatal dopamine and substantia nigra cell loss after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in monkeys: a possible role for the locus coeruleus in the progression of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Acoustic Stimulation; Animals; Corpus Striatum; Dopami | 1991 |
Effect of clonidine and atropine on rest tremor in the MPTP monkey model of parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Atropine; Clonidine; Disease Models, Animal; | 1991 |
Cyclohexyladenosine reduces MPTP induced tremor in dogs.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adenosine; Animals; Dogs; Reference Values; Time Facto | 1990 |
Symptoms and behavioral features induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in an old Java monkey [Macaca cynomolgus fascicularis (Raffles)].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aging; Animals; Behavior, Animal; Emotions; Eye Moveme | 1986 |
Failure of SKF 38393-A to relieve parkinsonian symptoms induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the marmoset.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzaze | 1985 |